/CAPR

Capricor Therapeutics Inc

CAPR

$8.37USD↑+0.84%+0.07 today

MARKET CAP

486.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$8 – $9

52W RANGE

$3

$40

AI Summary

Stalk

StalkMedium

CAPR remains in a deep Stage 4 decline with all moving averages sloping downward and price trading below key MAs. Extreme oversold readings suggest a tactical bounce, but the long-term trend stays bearish. Mean-reversion eligibility forces a bullish medium-term bias, permitting only countertrend entries. Short-term execution is deferred until we see support confirmation or an initial relief rally into falling EMAs.

↑Share price jumped 97% post-FDA application amendment; Cantor Fitzgerald set $28 target.
↑HOPE-3 data showed Deramiocel slowed DMD upper-limb decline by 54%.
↓Q2 operating expenses rose 55% YoY to $42.9 M, driving a $40.7 M net loss ($0.70/share).

Full analysis →

Buying

7

institutions

Selling

4

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	4.15 M	99.81 M	+723.25 K	-4.0%	0.00%
CA Citadel Advisors LLC Q2 2026	BUY	1.55 M	37.23 M	+106.21 K	-14.9%	0.00%
PA Perceptive Advisors LLC Q2 2026	BUYNEW	1.50 M	36.12 M	+1.50 M	+0.0%	0.54%
BA Balyasny Asset Management L.P. Q2 2026	BUY	486.84 K	11.72 M	+189.71 K	+29.8%	0.01%
MM Millennium Management LLC Q2 2026	BUY	402.23 K	9.69 M	+45.87 K	-10.6%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	362.50 K	8.69 M	+18.89 K	-9.0%	0.00%
WP Woodline Partners LP Q2 2026	SELL	138.77 K	3.34 M	+-136.54 K	-60.1%	0.01%
PA Point72 Asset Management, L.P. Q2 2026	SELL	94.72 K	2.28 M	+-726.46 K	-90.9%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUYNEW	45.20 K	1.37 M	+45.20 K	+0.0%	0.00%
AC Aqr Capital Management LLC Q2 2026	SELL	8.95 K	215.47 K	+-1.07 K	-29.3%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-18.11 K	-100.0%	0.00%